Long-term clinical results of coronary angioplasty with sirolimus-eluting stents in patients with Type 2 diabetes mellitus

Abstract

Aim. To assess the long-term results of coronary artery stenting (CAS) with drug-eluting stents (DES) in patients with coronary heart disease (CHD) and Type 2 diabetes mellitus (DM-2).Material and methods. CAS results were analyzed for 99 male and female CHD patients with angina and DM-2. In total, 78 sirolimus-eluting stents were implanted in 53 patients, and 57 non-DES were implanted in 46 individuals. In both groups, lethality and complication incidence were assessed, including the rates of recurrent angina, myocardial infarction, coronary artery bypass graft surgery, repeated endovascular intervention (EI) in the first 12 months after coronary angioplasty and in 2,5 years after EI.Results. DES usage reduced 12-month incidence of severe cardiovascular events (CVE) from 28,9% to 9,4%, and recurrent angina incidence – from 37,8% to 17%. Decrease in severe CVE rates was explained by reduction in repeated CA angioplasty – from 22% to 5,7%. In DES group, reduced long-term incidence was observed for severe CVE – from 40% to 18,9% and recurrent angina – from 44,4% to 22,6%.Conclusion. Endovascular myocardial revascularization with DES reduced 12-month risk of severe CVE and recurrent angina in patients with CHD and DM-2. This positive tendency remained for at least 2,5 years after coronary angioplasty.

Keywords

• coronary heart disease
• type 2 diabetes mellitus
• coronary artery angioplasty
• drug-eluting stents.